Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: The Intergroupe Francophone du Myélome experience

Journal of Clinical Oncology

Volumn 31, Issue 22, 2013, Pages 2806-2809

  Avet Loiseau, Hervé ^a   Hulin, Cyrille ^b   Campion, Loic ^c   Rodon, Philippe ^d   Marit, Gerald ^e   Attal, Michel ^a   Royer, Bruno ^f   Dib, Mamoun ^g   Voillat, Laurent ^d   Bouscary, Didier ^h   Caillot, Denis ^j   Wetterwald, Marc ^d   Pegourie, Brigitte ^k   Lepeu, Gerard ^l   Corront, Bernadette ^d   Karlin, Lionel ^m   Stoppa, Anne Marie ⁿ   Fuzibet, Jean Gabriel ^o   Delbrel, Xavier ^p   Guilhot, Francois ^q   Kolb, Brigitte ^r   Decaux, Olivier ^s   Lamy, Thierry ^s   Garderet, Laurent ⁱ   Allangba, Olivier ^d   Lifermann, Francois ^d   Anglaret, Bruno ^t   Moreau, Philippe ^u   Harousseau, Jean Luc ^c   Facon, Thierry ^v   more..

^a CHU RANGUEIL   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UMR INSERM U892 CNRS 6299   (France)

^d CENTRE HOSPITALIER   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h Institut Cochin   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j DIJON UNIVERSITY HOSPITAL   (France)

^k GRENOBLE UNIVERSITY HOSPITAL   (France)

^l CENTRE HOSPITALIER D AVIGNON   (France)

^m HOSPICES CIVILS DE LYON   (France)

ⁿ INSTITUT PAOLI CALMETTES   (France)

^o UNIVERSITY HOSPITAL OF NICE   (France)

^p CENTRE HOSPITALIER DE PAU   (France)

^q POITIERS UNIVERSITY HOSPITAL   (France)

^r REIMS UNIVERSITY HOSPITAL   (France)

^s RENNES UNIVERSITY HOSPITAL   (France)

^t CENTRE HOSPITALIER DE VALENCE   (France)

^u NANTES UNIVERSITY HOSPITAL   (France)

^v LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CHROMOSOME 13; CHROMOSOME 17; CHROMOSOME DELETION; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CHROMOSOME ABERRATION; DISEASE FREE SURVIVAL; GENE TRANSLOCATION; GENETICS; MORTALITY; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; DISEASE-FREE SURVIVAL; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSLOCATION, GENETIC;

EID: 84884793545     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.2598     Document Type: Article

References (13)

1. Avet-Loiseau H, Li C, Magrangeas F, et al: Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 27:4585-4590, 2009
2. Dewald GW, Kyle RA, Hicks GA, et al: The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66:380-390, 1985
3. Sawyer JR, Waldron JA, Jagannath S, et al: Cytogenetic finding in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82:41-49, 1995
4. Laï JL, Zandecki M, Mary JY, et al: Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 85:2490-2497, 1995
5. Calasanz MJ, Cigudosa JC, Odero MD, et al: Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations. Genes Chromosomes Cancer 18:84-93, 1997
6. Gertz MA, Lacy MQ, Dispenzieri A, et al: Clinical implications of t(11;14)(q13;q32), t(4; 14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106:2837-2840, 2005
7. Fonseca R, Blood E, Rue M, et al: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569-4575, 2003
8. Hanamura I, Stewart JP, Huang Y, et al: Frequent gain of chromosome band 1q21 in plasmacell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108:1724-1732, 2006
9. Avet-Loiseau H, Attal M, Moreau P, et al: Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myélome. Blood 109:3489-3495, 2007
10. Facon T, Mary JY, Hulin C, et al: Superiority of melphalan and prednisone chemotherapy plus thalidomide over melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma: Results of a randomised IFM trial. Lancet 370: 1209-1218, 2007
11. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
12. Avet-Loiseau H, Leleu X, Roussel M, et al: Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 28:4630-4634, 2010
13. Mateos MV, Gutiérrez NC, Martín-Ramos ML, et al: Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood 118:4547-4553, 2011